BioLineRx (BLRX) Change in Intangibles (2013 - 2023)

BioLineRx's (BLRX) quarterly Change in Intangibles came in at -$2000.0 in Q4 2023, up 98.83% year-on-year from -$1005.9 in Q4 2022, and up 92.31% quarter-over-quarter from -$26000.0 in Q3 2023.

BioLineRx (BLRX) Change in Intangibles (2013 - 2023) Analysis & Trends

BioLineRx's Change in Intangibles history runs 8 years deep, the most recent figure standing at -$2000.0 for Q4 2023.

  • On a quarterly basis, Change in Intangibles rose 98.83% year-over-year to -$2000.0 in Q4 2023; TTM through Dec 2023 was -$181000.0, a 98.22% increase from a year earlier, with the FY2025 full-year figure at -$2000.0, down 100.0% from the prior year.
  • Change in Intangibles improved to -$2000.0 in Q4 2023 per BLRX's latest filing, from -$26000.0 in the prior quarter.
  • Across five years, Change in Intangibles topped out at -$2000.0 in Q4 2023 and bottomed at -$171000.0 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Intangibles (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -66,508.31
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 BioLineRx 7.05 Bn 7.06 Bn 154,000.00 -

Historic Data

Download Data
DateValue
Dec 31, 2023 -2,000.00
Dec 31, 2023 -2,000.00
Sep 30, 2023 -26,000.00
Sep 30, 2023 -26,000.00
Jun 30, 2023 -56,000.00
Jun 30, 2023 -56,000.00
Mar 31, 2023 -97,000.00
Mar 31, 2023 -97,000.00
Dec 31, 2022 -171,000.00
Dec 31, 2022 -171,000.00
Sep 30, 2022 -14,000.00
Sep 30, 2022 -14,000.00
Dec 31, 2018 -10.00 Mn
Dec 31, 2018 -10.00 Mn
Sep 30, 2018 -3,000.00
Sep 30, 2018 -3,000.00
Jun 30, 2018 -8,000.00
Jun 30, 2018 -8,000.00
Mar 31, 2018 -29,000.00
Mar 31, 2018 -29,000.00